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ABSTRACT
The transactivator responsive region (TAR) present
inthe50-NTRoftheHIV-1genome represents apoten-
tial target for antiretroviral intervention and a model
system for the development of specific inhibitors of
RNA–protein interaction. Earlier, we have shown that
an anti-TAR polyamide nucleotide analog (PNATAR)
conjugated to a membrane transducing (MTD) pep-
tide, transportan, is efficiently taken up by the cells
and displays potent antiviral and virucidal activity
[B. Chaubey, S. Tripathi, S. Ganguly, D. Harris,
R. A. Casale and V. N. Pandey (2005) Virology, 331,
418–428]. In the present communication, we have
conjugated five different MTD peptides, penetratin,
tat peptide, transportan-27, and two of its truncated
derivatives, transportan-21 and transportan-22, to a
16mer PNA targeted to the TAR region of the HIV-1
genome. The individual conjugates were examined
for their uptake efficiency as judged by FACScan
analysis, uptake kinetics using radiolabeled con-
jugate, virucidal activity and antiviral efficacy
assessed by inhibition of HIV-1 infection/replication.
While FACScan analysis revealed concentration-
dependent cellular uptake of all the PNATAR–peptide
conjugates where uptake of the PNATAR–penetratin
conjugate was most efficient as .90% MTD was
observed within 1 min at a concentration of 200 nM.
The conjugates with penetratin, transportan-21 and
tat-peptides were most effective as an anti-HIV viruci-
dal agents with IC50 values in the range of 28–37 nM
while IC50 for inhibition of HIV-1 replication was
lowestwithPNATAR–transportan-27(0.4mM)followed
by PNATAR–tat (0.72 mM) and PNATAR–penetratin
(0.8 mM). These results indicate that anti-HIV-1 PNA
conjugated with MTD peptides are not only inhibitory
to HIV-1 replication in vitro but are also potent viruci-
dal agents which render HIV-1 virions non-infectious
upon brief exposure.
INTRODUCTION
HIV-1 infection is spreading at an alarming rate and despite
the best efforts at prevention where statistical data conﬁrm a
steady increase in the number of new HIV-1 infected patients.
In 2004, around ﬁve million new infections were reported
(http://www.unaids.org/wad2004/EPIupdate2004_html_en/
epi04_02_en.htm) with >13000 new infections occurring
daily. The rate of new infection depicts the failure of existing
and approved methods to control the spread of the deadly
virus. Highly active antiretroviral therapy (HAART) continues
to demonstrate increased clinical efﬁcacy due to the continu-
ous introduction of new antiretroviral agents (1). However,
the efﬁcacy of new treatments does not assist in preventing
the spread of the disease and the cost of drug therapy which is
prohibitive for a vast majority of acquired immunodeﬁciency
syndrome (AIDS) patients globally. Given this bleak scenario,
strategies should be rapidly developed to reduce the number of
newly infected individuals. Developing new virucidal agents
to be used as topical formulations during sexual contact, the
primary route of new infection, is an essential part of any such
strategy (2). Recently, enfuvirtide (Fuzeon ) was approved
by FDA as an HIV-1 entry inhibitor. This 36mer peptide
directed against the HIV-1 glycoprotein gp41 (3) is adminis-
tered by subcutaneous injection and is currently the only AIDS
drug which exerts its action outside the target cell prior to
infection. Besides this, a number of topical microbicides of
the NNRTI class (4,5) and surfactants (6) are reported to have
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This situation warrants the exploration of alternative strat-
egies for combating HIV infection, one of which involves an
in-depth critical analysis of non-mutable, highly conserved
regulatory regions of the HIV genome resistant to mutational
changes. The targeting of such regions by inhibitory agents
logically constitutes a feasible strategy for halting viral rep-
lication. The unique 50 (U5) non-translated region (1–333 nt)
of the HIV-1 genome comprises a number of regulatory
regions essential for replication. These critical domains
include (i) the primer-binding site (183–201 nt), essential
for tRNA3
Lys-primed initiation of reverse transcription (7–9),
(ii) the A-loop (168–173 nt) located upstream of the primer
binding site (PBS) and essential for the selection and
interaction of tRNA3
Lys primer (10), (iii) the LTR sequences
at the 50 and 30 ends of the genome which are essential for viral
transcription and integration (11) and (iv) the transactivation
responsive region (TAR) essential for gene expression via
transcriptional activation (12,13) and which also plays an
additional role in the initiation of reverse transcription (14).
Many approaches have been used in attempts to arrest retro-
viral replication and prominent among them is the antisense
strategy (15,16). In the quest for attractive antisense agents,
Nielsen et al. (17) ﬁrst introduced polyamide nucleic acids
(PNA) in 1991 and the PNAs were subsequently shown to
exhibit improved target afﬁnity, increased duplex stability,
nuclease resistance and superior pharmacokinetic properties
compared with other antisense agents. We have previously
used PNA to target two critical sites within the 50-untranslated
region of the HIV-1 genome. We have reported that PNA as
well as PNA–DNA chimera complementary to the primer-
binding site of the HIV genome can completely block priming
by tRNA3
Lys (18–20). We also targeted another equally impor-
tant non-mutable region, TAR, and have shown that anti-
PNATAR inhibits the tat-mediated transactivation of HIV-1
LTR transcription by efﬁcient sequestration of TAR (21).
Additionally, we were able to prove that a 16mer PNA com-
pletely blocks the loop and bulge region of TAR in contrast to
its shorter analogs, viz. 15, 13 and 12mer, which were also
found to be effective in blocking transactivation, albeit to a
lesser degree (22). Although PNAs have enormous potential as
antisense agents, the success of PNA-mediated gene therapy
requires efﬁcient cellular uptake, which has hitherto presented
a major barrier to success in strategies employing the use of
PNAs as potential therapeutic agents. In order to improve
cellular uptake of PNA targeted to the TAR region of the
HIV-1 genome we have earlier conjugated an anti-TAR
PNA with Transportan, a 27 amino acid membrane transduc-
ing (MTD) peptide. We also demonstrated successful in vitro
inhibition of HIV-1 replication using this conjugate (23,24).
In the present communication, a 16mer anti-TAR PNA
complementary to the minimal functional TAR sequence,
comprising the apical stem-loop and bulge regions, has
been conjugated with ﬁve different carrier peptides. The con-
jugated PNA effectively permeates the cellular membrane and
is able to inhibit HIV-1 replication in infected cells in vitro.I n
addition, the PNATAR–peptide conjugates are able to penetrate
HIV-1 virion particles, resulting in effective inactivation
of viral infectivity (24). Since, our main goal is to develop
various derivatives of anti-HIV-1 PNAs as effective antiviral/
virucidal agents for intervention of HIV-1 infection, all impor-
tant aspects related to drug delivery of this class of compounds
need to be explored extensively. One of the main obstacles
to the success of PNA as clinically relevant agents is their poor
cellular uptake. Therefore, this issue needs to be addressed
before designing experiments for animal models. We have
used ﬁve different cell-penetrating peptides as delivery vec-
tors. All the peptides besides transportan are shorter than
transportan. The use of shorter peptides as an effective
cargo for PNA biodelivery will be desirable as they are
expected to elicit little or no immunologic response when
used in animal models. Penetratin, a well-studied cell-pene-
trating peptide derived from the homeodomain, is common to
all homeoproteins (25,26). We have also used the highly basic
13mer tat-peptide (48–60 amino acids) derived from the
86 amino acid HIV-1 tat protein. This peptide has been
shown to actively traverse membranes of various cell types
(27). The sequence contains six arginine and two lysine resi-
dues, conferring a highly cationic character to this peptide.
Transportan-27, is a chimeric peptide containing a 13 amino
acidpeptide derived from galanin,and a 14 amino acid peptide
derived from mastoparan (wasp venom) connected via a lysine
residue (23,24). Two transportan analogs, one having a dele-
tion in the galanin arm (Transportan-21) (28) and the other
having a deletion in the mastoparan arm (Transportan-22), are
included in this study. While Transportan-21, has been
described earlier (28), Transportan-22, was designed and syn-
thesized for this study to examine the effect of deleting the
cationic domain comprising the six C-terminal amino acids of
the mastoparan peptide. The antiviral and virucidal properties,
as well as cellular uptake kinetics of these ﬁve conjugates were
evaluated extensively.
MATERIALS AND METHODS
Designing of PNAs and PNA conjugates
Sequences of PNATAR, PNATAR–MTD peptides and ﬂuores-
cein labeled PNATAR–MTD peptides are shown in Figure 1.
The 16mer penetratin (RQIKIWFQNRRMKWKK) and 13mer
tat-peptide (GRKKRRQRRRPPQ) were purchased from
BACHEM Biosciences Inc. Transportan-27 (GWYLNSA-
GYLLGK(e-Cys)INLKALAALAKKIL) and its truncated
derivatives Transportan-21 (AGYLLGK(e-Cys)INLKALAA-
LAKKIL) and Transportan-22 (GWYLNSAGYLLGK(e-
Cys)INLKALAAL) were obtained from Applied Biosystems.
A cysteine residue was incorporated at the N-terminus of
the peptides and the –SH group was activated with 3-nitro
pyridine sulphenyl groups (Scheme 1). The peptides with 3-
nitro-2-pyridinesulfenyl (NPYS) group are reported to react
rapidly with thiols to form disulﬁde linkage (29). Three PNAs
purchased from Applied Biosystems were Fluorenylmethy-
loxycarbonyl (Fmoc)-O-Cys-TCC-CAG-GCT-CAG-ATC-T,
Ac-Cys-TCC-CAG-GCT-CAG-ATC-T, and Ac-Cys-TCC-
CAG-GCT-CAG-ATC-T-Tyr. The Fmoc-O-Cys-TCC-CAG-
GCT-CAG-ATC-T was used to attach ﬂuorescein with
8-amino-2, 4-dioxaoctanoic acid (egl) linker at the 50 N-
terminus following removal of the Fmoc protecting group.
Ac-Cys-TCC-CAG-GCT-CAG-ATC-T-Tyr was used for
introducing radioiodine in the aromatic ring of Tyr residue at
the C-terminus. The Ac-Cys-TCC-CAG-GCT-CAG-ATC-T is
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PNAs had Cys residue at the N-terminus, which provides an
activated –SH group for conjugation with transporter peptides.
Fluorescein labeling of PNA
Fmoc-O-Cys-TCC-CAG-GCT-CAG-ATC-T sequence was
used for linking ﬂuorescein with egl linker. The ﬂuorescein
was attached to the PNA molecule while still immobilized on
MBHAresin(polystyrenebeads carrying4-methylbenzhydryl
amine). First, the Fmoc group was removed by treating with
20% piperidine in N,N0-Dimethylformamide (DMF) (1 ml) for
5 min. After washing the column with DMF (3· 1 ml), 300 ml
of DMF containing 1.66% (w/v) 5-carboxy ﬂuorescein suc-
cinimidyl ester (Molecular Probes, Eugene, OR) and 8.3%
diisopropyl ethylamine (v/v) was added to the resin and incu-
bated for 1 h with occasional shaking. The labeling solution
was discarded and the resin was washed with DMF and ﬁnally
with dichloromethane (DCM). The resin was further treated
with 10% triﬂuoro acetic acid (TFA) and 2% m-cresol in DCM
(100 ml) to remove the trityl group from the terminal cysteine
as well as the Bhoc (benzhydrylcarbonyl) protecting groups
from PNA. The ﬂuorescein labeled PNA was released from the
resin by treating with TFA: m-cresol (4:1) for 2 h and the
ﬂuoresceinated PNA was precipitated by the addition of 5-
fold excess of dry cold ether. The ﬂuorescein-tagged PNA
was further conjugated with different MTD peptides as
described below.
Synthesis of PNA-peptide conjugates
All the solvents used were degassed prior to use by bubbling
helium gas for 10 min. PNA (1 mmol, 1 eq.) dissolved in 1:1
NMP-H2O to a ﬁnal concentration of 1 mM (1.0 ml) was
supplemented with 1.3 eq. of NPYS-peptide dissolved in N-
methylpyrrolidinone(NMP)toaﬁnalconcentrationof10mM.
Finally, 100 ml of 1 M sodium acetate buffer (pH 5.0) was
added to it and the solution was vortexed and incubated at
40 C for 3 h in the dark. The reaction was quenched by
addition of 5% degassed aqueous TFA (ﬁnal conc. 650 mM)
and the conjugate was puriﬁed by high-performance liquid
chromatography using YMC guardpak ODS-AQ C18 column
(S-3 mm, 12 nm, 4· 50 mm) using water: acetonitrile gradient
(containing 0.5% acetic acid v/v) with the column temperature
maintained at 45 C. The fractions containing the conjugate
were pooled and lyophilized and stored at  20 C. During the
puriﬁcation the triﬂuoroacetate is converted to acetate salt to
eliminate the toxicity related with triﬂuoroacetate. The quan-
titation of PNA was done by measuring OD at 260 nm divided
by molar extinction coefﬁcient [150.6 ml/(mmol · cm)] for
PNA. The purity of the conjugated product was examined by
mass spectroscopy on a Perspective biosystems voyager
DE matrix-assisted laser desorption ionization time-of-ﬂight
(MALDI-TOF) system using sinapinic acid matrix.
Preparation of
32P-labeled RNA-TAR
The plasmid pEM-7 encoding the HIV-1 TAR under the con-
trol of the T7 promoter (30) was used for preparing the RNA
Figure 1. Sequence of anti-PNATAR used in the present study along with
the variations: (i) PNATAR–MTD peptide conjugate, (ii) Fluorescein-tagged
PNATAR–MTD peptide and (iii) I
125-labeled PNATAR–MTD peptide.
Scheme 1. Mechanism of conjugation chemistry for PNA–MTD peptides. The peptide moiety has cysteine at its N-terminus and it is activated by incorporating an
-NPYSgroup.ThePNAhasaterminalcysteineatits50 end.Inaredoxreaction,theS-Slinkageisformedwhichisstableincellculturemediabutiseasilydegradedin
the reductiveintracellular environment. This degradation is critical for the peptide moiety to completeits task as a transportingvector, releasing the PNA inside the
cell. Upon reduction of the disulfide bond, the PNA is released and migrates towards its target.
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pEM-7 was linearized with HindIII and the
32P-labeled run-
off transcript was prepared using [a
32P]CTP and T7 RNA
polymerase kit according to manufacturer’s protocol (Roche
Molecular Biochemicals). After the transcription reaction,
the plasmid DNA was digested with 25 U of DNase I and
the labeled transcript was puriﬁed by phenol–chloroform
extraction followed by alcohol precipitation.
Gel retardation assay
The afﬁnity and speciﬁcity of the PNATAR–peptide conjugate
for its target was evaluated by gel electrophoretic mobility
shift analysis (EMSA). The
32P-labeled TAR- RNA (20 nM;
10000 Cerenkov c.p.m.) was incubated with increasing con-
centrations of PNATAR–peptide conjugate (penetratin and tat)
in a buffer containing 30 mM Tris–HCl (pH 8.0), 75 mM KCl,
5.5 mM MgCl2, 1.3 mM DTT, 0.01% NP-40 and 500 ng of
poly r(I-C) in a ﬁnal volume of 15 ml. After 30 min of incuba-
tion at 37 C, samples were subjected to gel electrophoresis on
6% polyacrylamide gel using the Tris–borate buffer system.
The RNA–PNA-peptide complex was resolved at a constant
voltage of 150 V at r.t. for 3 h and subjected to phosphor-
Imager analysis (Molecular Dynamics).
Reverse transcription of TAR-RNA
Reverse transcription catalyzed by HIV-1 RT was carried out
in the presence of individual PNATAR–peptide conjugates
(penetratin and tat-peptides) using TAR-RNA template
primed with 50 32P-labeled 18mer DNA primer as described
before (22). The individual PNATAR–peptide conjugates at the
indicated concentrations were pre-incubated with 10 nM of the
annealed template primer at room temperature in a reaction
buffer containing 50 mM Tris–HCl (pH 7.8), 10 mM DTT,
100 mg/ml BSA, 60 mM KCl and 5 mM MgCl2 and 100 mM
each of the 4 dNTPs. Reverse transcription was initiated by the
addition of 50 nM of HIV-1 RT. The reactions were performed
at 37 C and terminated by the addition of equal volume of
Sanger’s gel loading dye (31). The products were resolved on
8% polyacrylamide denaturing urea gel and visualized by
phosphoimaging (Molecular Dynamics).
Cell culture, transfection of 293T cells and purification
of HIV-1 virions
TheCEM CD4
+lymphocytes 12D7 (32) were growninRPMI-
1640 medium supplemented with 10% fetal calf serum (FCS),
4m ML-glutamine at 37 Ci n5 %C O 2 containing humidiﬁed
air. Early-mid log phase cells were harvested and washed with
an equal volume of PBS with Ca
2+ and Mg
2+. For making
pseudotyped HIV-1, 293T cells grown in complete DMEM
were co-transfected with pHIV-1JR-CSF-lucenv( ) (33) and
pVSV-G using the calcium phosphate transfection system
(Life Technologies). The culture supernatant was saved at
24, 48 and 72 h post-transfection and analyzed for p24 antigen
using the enzyme-linked immunosorbent assay p24 antigen
kit (Abbott Laboratories). The pseudotyped HIV-1 virions
were isolated from the culture supernatant by ﬁltration through
a 0.45 mm pore size PVDF membrane (Millipore) followed by
ultracentrifugation at 70000 g for 45 min. The viral pellet was
re-suspended in 2 ml of PBS and re-centrifuged through 5 ml
of 20% sucrose/PBS cushion for 30 min at 100000 g.
Cellular uptake studies of PNA-peptides
CEM cells grown in complete RPMI medium containing 10%
fetal bovine serum (FBS) were harvested, washed with PBS
and re-suspended in the same medium containing 2% FBS at a
cell density of 0.5 · 10
6 cells/ml. Cells were aliquoted in a
12-well costar microtiter plate at 0.5 · 10
6 cells per well and
incubated at 37 C with varying concentrations of ﬂuorescein-
tagged PNATAR–MTD peptide conjugates. At varying time
points the cells were harvested and washed with PBS buffer
and re-suspended in complete RPMI medium. The ﬂuores-
ceinated cells were counted by FACS analysis (FACScan)
on a Beckton Dickinson ﬂow cytometer. All the sets were
scanned in the presence of 1 mg of propidium iodide to ensure
that the uptake occurred in live cells only. Cell Quest Pro
software (Beckton Dickinson) was used to acquire and analyze
10
4 events detected by the FL1 detector (for FITC), which
excluded FL3 detector (propidium iodide).
Luciferase assay
Luciferase assays were performed using the Promega
luciferase assay kit and manufacturer’s protocol (Luciferase
Reporter assay system, Promega Corp., Madison, WI). Brieﬂy,
the cells were harvested, washed once with PBS and lysed by
addition of 250 ml of the 1· reporter lysis buffer (Promega).
Following incubation at 25 C for 15 min on a rocking shaker,
the lysates were centrifuged at15000 r.p.m.for 10 min and the
supernatants were collected in fresh tubes. Luciferase assay
was performed by adding 100 ml of the luciferase substrate to
25 ml of each samples in a 96-well Fluorotec plate, and the
light emission was measured using a Packard top count ﬂuo-
rescence counter. The total light units were normalized by the
total protein content in the extract.
Uptake kinetics
The PNATAR–peptide conjugates and PNATAR were labeled
with [
125I] using the Na[
125I] and the chloramine-T labeling kit
from ICN. For radiolabeling, 0.5 nmol of the conjugate and
0.28 nmol of [
125I] (0.5 mCi) were reacted in the presence of
2.8 nmol of chloramine-T for 1 min and quenched by addition
of 62 nmol of sodium metabisulphite according to manufac-
turer’s protocol. The labeled conjugate was puriﬁed using
NAP-10 gel ﬁltration (Amersham-Pharmacia) and C18 reverse
phase columns. The ﬁnal product was quantiﬁed by absorption
at260nmand thespeciﬁcradioactivitywas adjusted todesired
levels by adding unlabeled conjugate. For uptake experiments,
1 · 10
6 CEM cells were incubated with varying concentra-
tions of the radiolabeled conjugate at room temperature. After
30 s of incubation, each individual sample was ﬁltered through
a glass ﬁber ﬁlter (GF-B), washed extensively with PBS and
the amount of radiolabeled PNA conjugate internalized by the
cells was determined by gamma counting. The [S]0.9/[S]0.1
ratio and cooperativity index of the substrate at 0.9 Vmax
and 0.1 Vmax was determined by plotting the uptake versus
substrate concentration. Hill coefﬁcient (nH) was determined
from the Hill plot of uptake data.
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The effect of anti-TAR PNA on HIV-1 production was moni-
tored by infecting CEM cells with pseudotyped HIV-1 virions
expressing the ﬁreﬂy luciferase reporter gene, described
above. Brieﬂy, pseudotyped HIV-1 virions (100 ng p24) in
the presence of 10 mg of polybrene/ml were added to 0.5 · 10
6
CEM cells in a ﬁnal volume of 1.0 ml to achieve multiplicities
of infection (MOI) of 0.003. The cell cultures were incubated
at 37 C for 2 h, and spun down at 1250 r.p.m. The cells
were washed twice with 1· PBS and re-suspended in 1 ml
of RPMI medium containing 10% FBS and varying amounts
of PNATAR–peptide conjugate, anti-TAR PNA, or peptide
alone. At 48 h post-transfection, the cells were harvested
and the level of infection/viral gene expression was quanti-
tated by luciferase assay. In another experiment, the cells were
ﬁrst incubated with the PNATAR–peptides, anti-PNATAR,o r
peptide alone for 2 h. The cells were then spun down at
1250 r.p.m. and the cells were washed and infected with the
pseudovirus, as described above. After 2 h the cells were again
harvested and washed with PBS and re-suspended in culture
medium. The cells were incubated for 48 h, harvested and
processed as described above.
Determination of virucidal activity PNATAR–peptide
conjugates
To examine the virucidal activity of the conjugate, 150 mlo f
HIV-1 pseudovirus (14 ng, p24 eq.) was incubated with dif-
ferent concentrations of PNATAR–peptide conjugates at 37 C
for 1 h. The mixture was then ultracentrifuged at 100000 g for
1 h and the viral pellet was re-suspended in RPMI medium
containing CEM cells (0.5 · 10
6) and 10 mg polybrene in a
ﬁnal volume of 1 ml. The cells were incubated on a rocking
shaker at 37 C for 2 h, harvested, washed once with 1· PBS
and ﬁnally re-suspended in 1 ml fresh complete RPMI media
in a 12-well tissue culture plate. The cells were incubated in a
5% CO2-containing humidiﬁed incubator at 37 C for 48 h and
then harvested and washed with PBS. The washed cells were
lysed in 250 ml cell lysis buffer provided with the luciferase
assaykit(Promega)andthecelllysateswere assayed forﬁreﬂy
luciferase activity. The level of luciferase activity was nor-
malized by protein content of the extract (BCA protein assay,
Pierce). The data from three independent experiments were
evaluated for the determination of dose median-effect using
the Calcusyn software (Biosoft).
Calculation of median dose effect
The effect of PNATAR–MTD peptide concentrations on the
luciferase expression were analyzed using the Calcusyn soft-
ware (Biosoft) based on the median-effect. This software is
based on a median-effect equation developed by Chou (34,35)
for determining dose–effect relationship. The IC50 corre-
sponds to median-effect dose which is given with 95% con-
ﬁdence in the results. The equation used is fa/fu ¼ (D/Dm)
m,
where D is the dose of drug; Dm is the median-effect dose
signifying the potency determined from the x-intercept of the
median-effect plot; fa is the fraction effected by the dose while
fu is the unaffected fraction (fu ¼ 1   fa); m is an exponent
signifying the sigmoidicity of the dose–effect curve. The IC50
corresponds to median-effect dose which is given with its 95%
conﬁdence limit in the result table.
RESULTS
Binding specificity of the PNATAR–penetratin and
PNATAR–tat-peptide to TAR-RNA
In order to evaluate the binding afﬁnity of the PNATAR–
peptide conjugates to their target sequence, we performed a
gel mobility shift assay with internally
32P-labeled 82 bp long
TAR-RNA transcript (20 nM) and increasing concentrations
of PNATAR–peptide (penetratin and tat-peptides) conjugates
(Figure 2A). At an equimolar ratio of PNATAR–peptide to
TAR-RNA,  90% shift was achieved (lane 5). The same
binding pattern was observed in a gel shift assay with the
unconjugated PNATAR (data not shown), suggesting that the
conjugation with the transporter peptide does not inhibit bind-
ing to its target. Binding experiments were done for PNATAR–
transportan and its truncated derivatives and the results
revealed a pattern similar to those exhibited by the PNATAR–
penetratin and PNATAR–tat conjugates (data not shown).
Inhibition of reverse transcription of TAR-RNA in the
presence of PNATAR–peptide
Since reverse transcription of the viral RNA is blocked by
PNA bound to the template downstream of the reverse tran-
scription site (18,19), similar inhibition of reverse transcrip-
tion was expected with PNA–peptide conjugates. To examine
this contention, the 82mer TAR-RNA primed with
32P-labeled
18mer DNA primer was incubated in the absence and pre-
sence of increasing concentrations (20 and 50 nM) of individ-
ual PNATAR–peptide conjugates at 37 C for 30 min, followed
by initiation of reverse transcription by HIV-1RT (Figure 2B).
In the control lanes, (no PNATAR–peptide) primer extension
was not inhibited and complete synthesis product was formed
within 3 min. However, in presence of PNATAR–peptide, a
distinct pause was evident at position 30 of the RNA-TAR
loop just prior to the PNA binding site (22). These results
clearly demonstrate that conjugation of PNA with the MTD
peptide(s) does not reduce its target efﬁcacy or the halting of
reverse transcription at the site of binding.
Cellular uptake of PNATAR–peptide
We have previously shown that PNA conjugated with trans-
portan is efﬁciently taken up by cells (24). In order to explore
the suitability of other carrier peptides to further improve the
uptake of PNA, we conjugated anti-TAR PNA with four dif-
ferent MTD peptides and evaluated their uptake efﬁciency by
FACScan analysis. Each of the conjugates contained a ﬂuo-
rescein tag attached to the PNA molecule. The unconjugated
naked PNA with a similar ﬂuorescein tag was used as a con-
trol. The lymphocyte CEM cells were incubated with varying
concentrations (50–500 nM) of individual ﬂuorescein-tagged
PNATAR–peptide conjugates and the ﬂuorescence signals per
10000 cells were recorded by FACScan. Figure 3 displays
differential uptake patterns as judged by ﬂuorescence intensity
in the presence of individual PNATAR–peptide conjugates. For
instance, the PNATAR–penetratin conjugate exhibited  85%
cellular uptake at 150 nM while only 40–50% of cells were
found to be ﬂuorescence positive at similar concentrations of
PNATAR–tatandPNATAR–transportanconjugates(Figure3A).
The cellular uptake of the penetratin conjugate was the most
efﬁcient of the tested conjugates as a sharp linear increase in
Nucleic Acids Research, 2005, Vol. 33, No. 13 4349Figure 2. (A) SpecificityofinteractionofPNATAR–penetratinorPNATAR–tat-peptide withitstargetsequenceonthe HIV-1genomicRNA.Thebindingaffinityof
anti-PNATAR to the TAR-RNA was assessed by EMSA. PNATAR–peptide conjugates at varying concentrations (2.5, 5, 10, 20, 30 and 40 nM) were incubated with
20nMof
32P-labeledTAR-RNAfor30minat37 CinbindingbufferandsubjectedtonativePAGE.TheRNA–PNAcomplexeswereresolvedataconstantvoltageof
150 Vat r.t. and visualizedby phosphorImaging. (B) Primerextensionassay withTAR-RNAtemplatein the presencePNATAR–penetratinor PNATAR–tat-peptide.
The TAR-RNA template was first annealed with a 50 32P-labeled 18mer DNA and then incubated with indicated concentrations of PNATAR–peptide at 37 C for
30 min. Reverse transcription reactions were initiated under standard reaction condition as described in Materials and Methods. Reactions were carried out at 37 C
andstoppedafterindicatedtimepoints(min)byadditionof2·Sanger’sgelloadingdye.Reactionproductswereresolvedonan8%denaturingpolyacrylamide-urea
gel. Control samples represent reverse transcription in the absence of PNATAR–peptide. The positions of the labeled 18 and 30mer extension product are indicated.
The 30mer position corresponds to the beginning of the loop region of the TAR-RNA, which is selectively targeted by the antisense PNA.
Figure 3. ComparisonofuptakepatternsofPNATAR–peptideconjugatesinCEMcells.InpanelA,PNATAR–Penetratin,PNATAR–tat,andPNATAR–transportan-27
are compared. In panel B, PNATAR–transportan-22, PNATAR–transportan-21, and PNATAR–transportan-27 are compared. Cells (0.5 · 10
6) were incubated with
varying concentrations of fluorescein-tagged PNATAR–peptide conjugates in RPMI medium with 2% FCS at room temperature. Uptake of conjugate within 1 min
was evaluated by FACS analysis.
4350 Nucleic Acids Research, 2005, Vol. 33, No. 13the ﬂuorescence intensity was consistently noted at lower con-
centrations (50–100 nM) with  99% uptake at 200 nM within
1 min of incubation. Transportan was the second most efﬁcient
peptide carrier as PNATAR–transportan exhibited a linear
increase in the uptake at all the concentrations (50–500 nM)
ranging from 10 to 15% uptake at 50 nM to  99% at 500 nM.
Its truncated derivative, transportan-22, was equally efﬁcient
while transportan-21 displayed relatively poor cellular uptake
as compared to its parent peptide (Figure 3B). This suggests
that the hydrophobic domain of the galparan unit is indispens-
able and its deletion changes its uptake pattern relative to
the parent transportan peptide. Extending the incubation
period up to 5 min had no impact on the ﬂuorescence
intensity, indicating that cellular uptake is very rapid for all
the PNATAR–peptide conjugates.
It was further conﬁrmed that the incubation temperature had
no inﬂuence on the cellular uptake of each of the PNA–peptide
conjugates as ﬂuorescence intensity per 10000 cells did not
change signiﬁcantly when incubation was carried out at 4, 25
and 37 C (data not shown). Within 1 min of incubation the
uptake of PNATAR–peptide reaches a maximum at all the
tested temperatures, suggesting that the uptake does not
occur via receptor-mediated endocytosis, which is largely
inhibited at lower temperatures. To rule out the possibility
that the PNA–peptide conjugates adhere non-speciﬁcally
to the cell surface, falsely elevating ﬂuorescence readings, a
parallel experiment was carried out. Following incubation
with the individual ﬂuorescein-tagged PNA–peptide conju-
gates, cells were washed once with PBS containing 0.01%
trypsin, then twice with PBS and ﬁnally re-suspended in
RPMI media for FACScan. An 8–10% decrease in the ﬂuo-
rescence intensities was seen following the trypsin wash while
the overall uptake pattern remained unchanged, suggesting
that the major portion of the ﬂuorescence intensity observed
in the FACScan was due to cellular uptake of the individual
conjugates and not non-speciﬁc association with the cell
membrane (data not shown).
Uptake kinetics
The cellular internalization of penetratin, tat-peptide and
transportan has been reported to be uninhibited at 4 C
suggesting that the uptake mechanism does not involve
receptor-mediated endocytosis (25,26,36,37). In addition,
the rapid cellular internalization of penetratin as well as trans-
portan has been reported to remain unsaturated (25,26,37).
PNATAR–penetratin, having a net positive charge, is reported
to enter the hydrophobic membrane lipid environment follow-
ing interaction with negatively charged molecules on the cell
surface through a two-step process, phase transfer followed by
tryptophan-dependent translocation (38). A similar pattern is
expected when these peptide carriers are used as the vehicle to
deliver PNA into the cells. To determine this, the PNA moiety
of the individual PNA–peptide conjugates was labeled with
radioiodine (
125I) and used for quantitative evaluation of
their cellular uptake. Brieﬂy, 0.5 · 10
6 cells (lymphocytes)
were incubated with varying concentrations of radiolabeled
PNATAR–peptide conjugate at room temperature for 30 s fol-
lowed by rapid ﬁltration through the GF-B. The ﬁlters were
washed with PBS and the radioactivity within the cells was
determined by gamma counting. The results shown in Figure 4
represent the uptake kinetics obtained with individual PNA–
peptide conjugates. All the PNA–peptide conjugates yielded a
sigmoidal curve (Figure 4, left panel) suggesting a cooperative
interaction between the conjugate and the cellular membrane.
The cooperativity index (ratio of [S]0.9/[S]0.1) obtained with
individual conjugates suggest the amount of conjugate that
would be required for increasing the uptake velocity from
0.1 to 0.9 Vmax. The cooperativity indices varied from
2.5 to 10.6 with PNA–tat conjugate having the lowest
and the PNATAR–transportan-22 having the highest. The
PNATAR–penetratin and PNATAR–transportan-27 conjugates
displayed intermediate values of 4.0 and 6.33, respectively.
A Hill plot of the uptake data was generated to determine the
nH values for individual PNA–peptide conjugates (Figure 4,
right panel). The [S]0.5 value as well as nH for individual
PNA–peptide conjugate was determined from this plot. The
[S]0.5 values indicate the concentration of the conjugate at
which uptake velocity is half of Vmax. The [S]0.5 values in
the range of 285–430 nM were obtained with PNATAR–tat,
PNATAR–transportan-22 and PNATAR–penetratin conjugates
while conjugate with transportan and its truncated derivative
transportan-21, exhibited [S]0.5 values in the range of 0.8–
1.5 mM. The nH values determined from the slope of the
Hill plot varied from 0.58 for PNATAR–transportan-21 to
2.29 for PNATAR–tat conjugate with an intermediate value
of 1.8 obtained for both PNATAR–penetratin and PNATAR–
transportan-22 conjugates. The nH >1 for PNATAR–tat,
PNATAR–penetratin and PNATAR–transportan-22 suggest
that these conjugates may have more than one interaction
site on the cellular membrane.
Inhibition of HIV-1 replication in vivo in the presence
of anti-PNATAR analogs
In order to evaluate the in vitro antiviral efﬁcacy of the
individual PNATAR–peptide conjugates, the growth media
for CEM cells infected with pseudotyped HIV-1 was supple-
mented with the conjugates. In this experiment, CD4
+ lym-
phocytes infected with highly infectious VSV-G pseudotyped
HIV-1 virus (carrying the ﬁreﬂy luciferase reporter gene) were
incubated with varying concentrations of individual PNATAR–
peptide conjugates. Similar experiments were performed
with unconjugated anti-PNATAR and peptide alone as controls.
Experiments were carried out for 48 h to assess the inhibition
of viral replication during this interval. Following the incuba-
tion, the cells were lysed and the cell extract was normalized
for total protein content and analyzed for quantitative levels of
luciferase expression. The luciferase activity obtained in the
infected cells in the absence of PNA was assigned an arbitrary
value of 100 while the other samples were given values rel-
ative to this control value. A substantial decrease in viral
replication was observed as the concentration of PNA conju-
gate was increased. Figure 5 shows the dose–effect curves
(left panel; Figure 5A) and the median-effect plot (right
panel; Figure 5B) obtained with individual conjugates. Addi-
tion of 100 nM PNATAR–penetratin to the culture media did
not inhibit HIV-1 replication but higher concentrations did
effectively inhibit viral replication. At 800 nM PNATAR–
penetratin,  50% inhibition is achieved. The same pattern
was achieved when the cells were ﬁrst incubated with
PNATAR–penetratin for 2 h prior to infection with the virus
Nucleic Acids Research, 2005, Vol. 33, No. 13 4351Figure 4. Uptake kinetics studies of PNATAR–penetratin, PNATAR–tat-peptide, PNATAR–transportan-21 and PNATAR–transportan-22 in CEM cells. The
125I-labeled conjugate wasincubated withCEM cells and the amountofconjugate taken up by the cells wasdeterminedfrom specific radioactivityofthe conjugate
asdescribedintheMaterialsandMethods.Theuptakeoftheconjugatewasplottedagainstthelogofconjugateconcentrationandthecooperativityindex([S]0.9/[S]
0.1)wasdetermined(leftpanels).Hillcoefficient(nH)wasdeterminedfromtheslopeoftheHillplotoftheuptakedatashownintherightpanels.Cooperativityindex
represents the ratio of the substrate at 0.9 Vmax and 0.1 Vmax while nH represents the concentration of the conjugate at which the velocity of the uptake is equal to
0.5 Vmax. PNATAR–transportan data (24) were provided for comparison.
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binding to its target sequence is rapid and effective (data
not shown). The pattern with the other PNATAR–peptides
was found to be the same and the IC50 values were calculated
using Calcusyn software are tabulated in Table 1.
The virucidal effects of different PNATAR–peptide
conjugates
The virucidal effects of PNATAR–peptide conjugates were
evaluated by treating the HIV-1 pseudovirus (14 ng,
eq. p24) with varying concentrations of PNATAR–peptide
conjugates (Figure 6). The treated virions were used to infect
the CEM cells. The infected cells were then incubated for 48 h
and lysed. The expression levels of a luciferase reporter gene
were measured in the cell lysates to evaluate the effect of
individual PNATAR–peptide conjugate on viral infectivity.
Untreated virions were used as a control in this experiment.
The IC50 for PNATAR–peptide conjugate on viral infectivity
are tabulated in Table 1. As apparent from the median-effect
plot and dose–response curve, PNATAR–penetratin was highly
virucidal showing the dose median of 28.0 nM closely
followed by PNATAR–transportan-21 with a value of 34.0 nM
and by PNATAR–tat-peptide with a value of 37.0 nM. The
virucidal activity of PNATAR–transportan-21 is not congruent
with its pattern of reduced uptake compared to parent trans-
portan, as shown by FACScan studies, suggesting that the
mode of interaction with virus envelope is different from its
interaction with the cell membrane. The deletion of the cat-
ionic domain in the mastoparan unit shows that there is no
alteration in uptake pattern as suggested by FACScan studies
and the virucidal activity remains comparable to the parent
transportan. Although PNATAR–transportan-27 and PNATAR–
transportan-22 show dose median values of 66.0 and 72.0 nM,
respectively, these are still in the <100 nM range. The IC50
values for virucidal and antiviral activities are in a narrow
range not showing correlation with the uptake efﬁciency of
each of the peptides. The most plausible explanation is that
the peptides are used here as a cell-transducing vector and
once inside the cell the disulﬁde bond will be cleaved, leaving
the PNA free to reach its target. As the experiments were
donefor48h,the effectofrapidentry islikelytobeminimized
after 48 h.
DISCUSSION
AIDS is a sexually transmitted disease that has become a
global pandemic. The numbers of patients infected with HIV
are increasing at an alarming rate mainly due to transmission
Figure 5. (A) Dose–effect curve for antiviral efficacy of PNATAR–penetratin,
PNATAR–tat-peptide PNATAR–transportan-21 and PNATAR–transportan-22
conjugates. CEM cells were infected with VSV-G pseudotyped S1 strain of
HIV-1 and grown in the presence of increasing concentrations of PNATAR–
penetratin and PNATAR–tat-peptide (0–1000 nM). Cells were harvested, lysed
and assayed for luciferase expression 48 h post infection. The effect PNATAR–
peptide concentrations on the luciferase expression was analyzed using the
Calcusyn software (Biosoft). (B) Median-effect Plot: The IC50 values deter-
mined from the ratio of log of luciferase expression in treated cells (fa) and
untreated cells (fu) as a function of the log concentration of PNATAR–
penetratin, PNATAR–tat-peptide, PNATAR–transportan-21 and PNATAR–
transportan-22 conjugates were 0.8 , 0.70, 1.0 and 1.1 mM, and the linear
correlation coefficients, r, were 0.93, 0.87, 0.99 and 0.98, respectively.
Table 1. Comparative antiviral efficacy and virucidal activity of PNATAR in
presence of different peptides
PNATAR–peptide conjugate Antiviral efficacy Virucidal activity
IC50
(nM)
m r IC50
(nM)
m r
PNATAR–penetratin 800 2.8 0.93 28 0.69 0.98
PNATAR–tat-peptide 720 2.6 0.87 37 0.94 0.43
PNATAR–transportan-27 400 1.4 0.98 66 0.69 0.92
PNATAR–transportan-21 1000 0.6 0.99 34 0.46 0.79
PNATAR–transportan-22 1100 1.78 0.98 72 0.86 0.86
For carrying out antiviral efficacy experiments CEM cells were infected with
VSV-G pseudotyped S1 strain of HIV-1 and then grown in the presence of
increasing concentrations of PNATAR–MTD peptides. Cells were harvested,
lysed and assayed for luciferase expression 48 h post infection. The effects of
PNATAR–MTD peptide concentrations on the luciferase expression were ana-
lyzed using the Calcusyn software (Biosoft) based on Median-effect equation
of Chou (34,35). The IC50 values determined from the ratio of the log of
luciferase expression in treated cells (fa) and untreated cells (fu) as a function
of log concentration of PNATAR–MTD peptide. Sigmoidicity (m) of the dose–
effect curve is derived from slope of median-effect plot and values of 1, >1,
<1indicatehyperbolic,sigmoidal,andnegativesigmoidalshapes,respectively.
Linear correlation coefficient of the median-effect plot is represented by r
and a value of 1 indicates perfect conformity.
For carrying out virucidal activity experiments PNATAR conjugated with dif-
ferent peptides at varying concentrations (25, 50, 100, 250 and 500 nM) were
incubated at 37 C with HIV-1 virions for 2 h. The virion particles were spun
down by ultracentrifugation and then the virions were used for infection of
CEM cells for 48 h at 37 C in a 5% CO2 incubator. The cells were harvested,
lysedandassayedforluciferaseactivity.Themediandoseeffectwascalculated
using Calcusyn software program (Biosoft). Penetratin displays the greatest
virucidal efficacy among this group of MTD peptides.
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new infections due to sexual transmission (2) include: igno-
rance of the HIV status of the sexual partners, unavailability of
condoms and anti-HIV spermicides, and fear of confronting
male partners regarding safe sex prior to intercourse. Despite
massive efforts to develop an effective vaccine against HIV-1
(39), a vaccine that will confer long-term protective immunity
has yet to be developed. For these reasons, it is imperative to
develop a strategy that will minimize new infections. Along
these lines, efforts are underway to develop topical microbi-
cides (4–6) and some agents, such as (+)-calanolide A, are
advancing in clinical trials (5). This strategy will be helpful in
decreasing the number of new infections, a critical step
towards effective control of the AIDS epidemic. Antisense
technology has great potential as part of this prophylaxis strat-
egy and PNAs are proven antisense agents (40,41). Although
PNAs are very potent antisense molecules in vitro, they are
poorly internalized by cells (42). A number of methods for
their intracellular delivery have been developed which include
microinjection (43), electroporation (44), co-transfection
with DNA (45,46) and conjugation with transporter peptides
(23,24).
In the present study, we have used various MTD peptides
as delivery vectors for anti-HIV-1 PNA and have evaluated
their inﬂuence on the cellular uptake of PNA, as each
transporter peptide will alter both the biodeliveryand bioavail-
ability proﬁles of the PNA. Gel shift assays clearly indicated
that the conjugation with different MTD peptides does not
decrease the afﬁnity of the PNA for its target RNA sequence.
We have earlier shown that uptake of PNATAR–transportan
conjugate is temperature independent and not affected
by phenylarsine treatment of the cells suggesting non-
involvement of endocytosis or receptor-mediated internaliza-
tion of the conjugate (24). Similar uptake patterns were also
noted for PNATAR–penetratin and PNATAR–tat conjugates.
Our observations are consistent with the reported study on
the uptake of penetratin and transportan peptides (37) while
in disagreement with the nature of uptake of the tat-peptide
(36,47,48). Initially, Vive `s et al. (36), have shown that endo-
cytosis pathway is not involved in the uptake of tat-peptide
as no inhibition of uptake was noted at 4 C. Later, they con-
tradicted their own observations and suggested that entry of
tat-peptide is ATP and temperature dependent, likely invol-
vinganendocytoticmechanism(47,48).Recently,Wadiaetal.
(49) have demonstrated that the uptake of a large Tat–Cre
fusion protein (38 kDa) is mediated by lipid-raft dependent
micropinocytosis which is also inhibited at 4 C. However, in
our hands, the uptake of PNATAR–tat conjugate as determined
by FACScan analysis was found to be temperature indepen-
dent indicating that endocytosis pathways may not be opera-
tive for the conjugate. It is possible that the mode of uptake
for tat-peptide alone versus tat–PNA conjugates may differ
signiﬁcantly.
The uptake kinetics have revealed a sigmoidal curve for
all the ﬁve PNATAR–MTD conjugates indicating a common
uptake mechanism, likely involving cooperative interaction
between the cellular membrane and the conjugate. The
observed cooperativity of uptake may be due to micelle forma-
tion, which requires a concentration threshold of components.
A cooperativity index of 2.5 observed with PNATAR–tat con-
jugate suggests that in order to increase the uptake velocity
from 0.1 to 0.9 Vmax, only a 2.5-fold increase in the concen-
tration of conjugate is required. The cooperativity indices
with other PNATAR–peptide conjugates were in the range of
4.0–10.6. This pattern of sigmoidal uptake is expected to be
more effective than a hyperbolic curve which would require
Figure 6. (A) Dose–effect curves for virucidal activity of PNATAR–peptides.
The VSV-G pseudotyped HIV-1 virions were first incubated with indicated
concentrations of individual PNATAR–peptide conjugates as described in the
Materials and Methods. The treated virions were used to infect CEM cells
(0.5 · 10
6 cells). The infected cells were grown for 48 h, harvested, lysed
and assayed for luciferase activity. The level of luciferase expression as a
function of virucidal effect of individual PNATAR–peptide concentration on
HIV-1 virions in CEM cells infected with treated and untreated virions, was
analyzed using the Calcusyn software (Biosoft). (B) Median-effect Plots for
virucidal activity: The IC50 for virucidal effect of individual PNATAR–peptide
conjugates was determined from the ratio of the log of luciferase expression in
CEM cells infected with treated (fa) and untreated HIV-1 virions (fu) as a
function of the log concentration of PNATAR–peptide (Table 1).
4354 Nucleic Acids Research, 2005, Vol. 33, No. 13a muchhigher concentration of the substrate (90-fold increase)
to achieve similar velocity from 0.1 to 0.9 Vmax. The anti-
HIV-1 PNA in this study was designed to target the TAR
region of the HIV-1 genome. Conjugation of this PNATAR–
MTD peptides facilitated intracellular delivery with the
goal of inhibiting HIV-1 production by down regulation of
tat-mediated transactivation of HIV-1 transcription. All the
conjugates were indeed inhibitory to HIV-1 production
when supplemented in cell culture. We have shown that infec-
tion of CEM cells by HIV-1 virions was also drastically
reduced in the presence of PNATAR–transportan-27 conjugate
(23,24). Similar results were also obtained with PNA conju-
gated with penetratin, tat, and two truncated derivatives
of transportan. However, PNATAR–penetratin conjugate was
the most effective virucidal agent displaying an IC50 of28nM.
The rendering of HIV-1 virions as non-infectious indicates
that these conjugates may either interfere with viral entry
by altering or disrupting the viral envelope or may permeate
the virus envelope and bind to the target sequence on the viral
genome. We have earlier shown that endogenous reverse
transcription of HIV-1 virions pretreated with PNATAR–
transportan conjugate is completely aborted in the TAR region
since the PNA conjugate bound to the TAR region cannot be
displaced by reverse transcriptase (24).
The potent virucidal activity displayed by this class of
PNA–MTD conjugates may not be unique to HIV-1 but
may also be relevant for other enveloped viruses. Most cur-
rently available anti-HIV drugs do not inactivate circulating
HIV-1 virions and their mode of action is limited to inhibiting
HIV-1 replication after the infection (HIV entry) has taken
place. The only exceptions to this are entry inhibitors that
block HIV-1 entry into the cells without inactivating the virion
particles (50–52) and enfuvirtide is the only entry inhibitor
currently in clinical use. In this context, anti-HIV-1 PNAs
conjugated with MTD peptides are distinct in that these are
not only inhibitory to intracellular HIV-1 replication but may
also have the ability to block HIV-1 infection by rendering
HIV-1 virions non-infectious.
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